Suppr超能文献

接受舌下免疫治疗的儿童对不同草花粉过敏原成分的特异性IgE反应。

Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy.

作者信息

Marcucci Francesco, Sensi Laura, Incorvaia Cristoforo, Dell'Albani Ilaria, Di Cara Giuseppe, Frati Franco

机构信息

Spin-Off ATRP Srl, Allergic Tests Research and Production, Perugia, Italy.

出版信息

Clin Mol Allergy. 2012 Jun 13;10(1):7. doi: 10.1186/1476-7961-10-7.

Abstract

BACKGROUND

Grass pollen is a major cause of respiratory allergy worldwide and contain a number of allergens, some of theme (Phl p 1, Phl p 2, Phl p 5, and Phl 6 from Phleum pratense, and their homologous in other grasses) are known as major allergens. The administration of grass pollen extracts by immunotherapy generally induces an initial rise in specific immunoglobulin E (sIgE) production followed by a progressive decline during the treatment. Some studies reported that immunotherapy is able to induce a de novo sensitisation to allergen component previously unrecognized.

METHODS

We investigated in 30 children (19 males and 11 females, mean age 11.3 years), 19 treated with sublingual immunotherapy (SLIT) by a 5-grass extract and 11 untreated, the sIgE and sIgG4 response to the different allergen components.

RESULTS

Significant increases (p < 0.001) were detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6, while sIgE levels induced in response to Phl p 7 and Phl p 12 were low or absent at baseline and unchanged following SLIT treatment; no new sensitisation was detected. As to IgG4, significant increases were found for Phl p2 and Phl p 5, while the increase for Phl p 12 was not significant. In the control group, no significant increase in sIgE for any single allergen component was found.

CONCLUSIONS

These findings confirm that the initial phase of SLIT with a grass pollen extract enhances the sIgE synthesis and show that the sIgE response concerns the same allergen components which induce IgE reactivity during natural exposure.

摘要

背景

草花粉是全球呼吸道过敏的主要诱因,含有多种过敏原,其中一些(来自早熟禾的Phl p 1、Phl p 2、Phl p 5和Phl p 6,以及其他草类中的同源物)被认为是主要过敏原。通过免疫疗法给予草花粉提取物通常会导致特异性免疫球蛋白E(sIgE)产生最初上升,随后在治疗过程中逐渐下降。一些研究报告称,免疫疗法能够诱导对先前未识别的过敏原成分产生从头致敏。

方法

我们调查了30名儿童(19名男性和11名女性,平均年龄11.3岁),其中19名接受了5种草提取物的舌下免疫疗法(SLIT)治疗,11名未接受治疗,检测了他们对不同过敏原成分的sIgE和sIgG4反应。

结果

检测到Phl p 1、Phl p 2、Phl p 5和Phl p 6有显著增加(p < 0.001),而对Phl p 7和Phl p 12的sIgE水平在基线时较低或不存在,SLIT治疗后未发生变化;未检测到新的致敏情况。关于IgG4,Phl p2和Phl p 5有显著增加,而Phl p 12的增加不显著。在对照组中,未发现任何单一过敏原成分的sIgE有显著增加。

结论

这些发现证实了草花粉提取物舌下免疫疗法的初始阶段会增强sIgE合成,并表明sIgE反应涉及自然暴露期间诱导IgE反应性的相同过敏原成分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63a5/3511885/f9e480829393/1476-7961-10-7-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验